← Back to Search

Alkylating Agent

rebastinib for Solid Tumors

Phase 1 & 2
Waitlist Available
Research Sponsored by Deciphera Pharmaceuticals LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 24 months
Awards & highlights

Study Summary

This trial is testing a new cancer drug, rebastinib, to see if it is safe and works well with carboplatin to treat solid tumors.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events (Part 1 and Part 2)
Objective response rate (ORR) (Part 2)
Secondary outcome measures
Area under the concentration-time curve (AUC) of rebastinib
Duration of response (DOR)
Maximum observed concentration (Cmax) of rebastinib
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Part 2Experimental Treatment2 Interventions
Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with carboplatin Triple-negative breast cancer Platinum-sensitive Ovarian cancer Mesothelioma
Group II: Part 1Experimental Treatment2 Interventions
Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) dosed in 21-day cycles in combination with carboplatin administered by IV infusion at either AUC5 or AUC6 once every 3 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rebastinib
Not yet FDA approved
Carboplatin
FDA approved

Find a Location

Who is running the clinical trial?

Deciphera Pharmaceuticals LLCLead Sponsor
16 Previous Clinical Trials
2,127 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
2019. "A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03717415.
~19 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top